Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Improving the frontline treatment of DLBCL

Umberto Vitolo • 2 Jul 2019
ICML 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma

Umberto Vitolo, MD, Città della Salute e della Scienza University Hospital, Turin, Italy, discusses the unmet needs in the first-line treatment of diffuse large B-cell lymphoma (DLBCL), and how therapy in the frontline setting can be improved beyond the standard of care, R-CHOP. He highlights how the variety of distinct subtypes of DLBCL should be molecularly targeted. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Umberto Vitolo

1:56
Copanlisib, rituximab, & bendamustine in transplant-ineligible R/R DLBCL
Umberto Vitolo • 10 Dec 2023
2:13
Rituximab ± lenalidomide as maintenance therapy in elderly patients with R/R FL
Umberto Vitolo • 10 Dec 2023
3:20
Bispecific antibodies in NHL: current insights and ongoing studies
Umberto Vitolo • 15 Jun 2023
1:31
The current state of treatment for limited-stage DLBCL
Umberto Vitolo • 15 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals